OpenAI is acquiring startup Orchestra Bio and will merge it with its life sciences platform Rosalind to build AI agents that help pharmaceutical teams coordinate drug development, from tracking trials to spotting problems.
OpenAI Acquires Orchestra Bio to Build AI Agents for Drug Development
OpenAI is acquiring startup Orchestra Bio and will merge it with its life sciences platform Rosalind to build AI agents that help pharmaceutical teams coordinate drug development, from tracking trials to spotting problems.
Monitoring item. The full text is not distributed. Extract and source below.